Brisbane, Australia-based ResApp intended to have its software, which uses a smartphone microphone to diagnose respiratory conditions based on coughs, well on its way through the FDA by now. But this past summer, the company’s big plans hit a major setback when the data came back from its landmark clinical trial, conducted at such austere institutions as Massachusetts General Hospital, Cleveland...
